You'd have to ask the NRC about that.
I think the issue is that at that point, the NRC had ended its partnership with CanSino, which is a viral vector vaccine along the same lines as the AstraZeneca vaccine. I think they were in discussions with AstraZeneca. I think you heard that from the president of the NRC. At that point, we were also simultaneously in discussion with Novavax, which ultimately has led to a successful completion. I think they were looking around for a partner that would come in and work with them on that.
What I meant in saying that is that if we had domestic capacity, of course we could scale up and rapidly produce vaccines here.